This study illustrates the feasibility of using remote symptom monitoring for evaluating patients with poor vs. other cytogenetic risk in routine care.
In this study, we used electronic patient-reported outcomes (ePRO) through a remote symptom monitoring program in MM patients experiencing variable levels of pain.
This study demonstrates the feasibility of gathering PROs with real-world data among a cohort of patients with AML using a remote symptom monitoring platform, across baseline prognostic and therapeutic factors.